Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: Programmed death ligand 1 (PD‐L1) immunohistochemistry has become a mandatory diagnostic test in the treatment of lung cancer. Several research initiatives have started to harmonise the five PD‐L1 immunohistochemistry assays that have been used in clinical trials. Here, we report data on interlaboratory and interassay concordance for commercial assays (‘assays’) and laboratory‐developed tests (LDT s) at 10 German testing sites. Methods and results: To assess interlaboratory concordance, a tissue microarray containing 21 pulmonary carcinoma specimens was centrally prepared. Pre‐cut sections were stained at 10 sites by the use of assays 28‐8, 22C3, SP 263, and SP 142, as well as 11 LDT s. Assay performance was evaluated with a second tissue microarray containing 11 cell lines with defined PD‐L1 expression. Quality control was centrally performed by manual and digital analyses. The assays yielded reproducible IHC staining patterns at all sites. In agreement with previous studies, 22C3, 28‐8 and SP 263 showed similar staining patterns, whereas SP 142 was distinct. Among the LDT s, six of 11 protocols showed staining patterns similar to those of assays 22C3 and 28‐8. Interlaboratory concordance of tumour cell scoring by use of a six‐step system was moderate (Light's κ = 0.43–0.69), whereas the clinically approved cut‐offs of ≥1% and ≥50% showed substantial concordance (κ = 0.73–0.89). Immune cell scoring by the use of SP 142 yielded moderate concordance (κ = 0.42). Conclusions: The data confirm the previously described staining patterns of the assays, and show that they can be reproducibly employed at different sites. LDT s with staining results similar to those of the assays are implementable, but have to be carefully validated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 2×
“Each route can explain a proportion of clinical responses, but no biomarker has been demonstrated to reliably identify non-responders.(5,11) Currently, PD-L1 immunohistochemistry (IHC) is the only clinically approved predictive biomarker for anti-PD-1/PD-L1 therapy.”
BackgroundMethodRimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764 · cited 1×
“This is in agreement with the other harmonisation studies and the literature.(14,15,18,24) Data on the staining patterns of the assays are accumulating:”
ResultBlank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Cited by
Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., Dubinett, S. M., Ferris, A., Gandhi, L., Garon, E. B., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0382-2 · Cited by 253
Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy333 · Cited by 197
Self-citationSholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Kossai, M., Radosevic-Robin, N., & Penault-Llorca, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100257 · Cited by 36
Metadata
- Authors
- Scheel, A. H., Baenfer, G., Baretton, G., Dietel, M., Diezko, R., Henkel, T., Heukamp, L. C., Jasani, B., Jöhrens, K., Kirchner, T., Lasitschka, F., Petersen, I., Reu, S., Schildhaus, H., Schirmacher, P., Schwamborn, K., Sommer, U., Stoss, O., Tiemann, M., Warth, A., Weichert, W., Wolf, J., Büttner, R., & Rüschoff, J.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2017-11-21
- Volume
- 72
- Issue
- 3
- Pages
- 449-459
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2752031457
- Cited by
- 80
- References
- 6
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer. https://app.cochat.ai/papers/10.1111/his.13375
- The paper
- Scheel, A. H., Baenfer, G., Baretton, G., Dietel, M., Diezko, R., Henkel, T., Heukamp, L. C., Jasani, B., Jöhrens, K., Kirchner, T., Lasitschka, F., Petersen, I., Reu, S., Schildhaus, H., Schirmacher, P., Schwamborn, K., Sommer, U., Stoss, O., Tiemann, M., . . . Rüschoff, J. (2018). Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer. Histopathology. https://doi.org/10.1111/his.13375
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.